6–38. 5]; p = 0.0141). Likewise in the Tryphaena phase 2 trial, among the 225 patients with HER2+ breast cancer treated with the combination of pertuzumab, trastuzumab and chemotherapy in the neoadjuvant setting only 13 had HER2+ IBC [47]. This evidence concerns the gene ERBB2 and breast carcinoma.